Anti-galectin-9 antibodies and uses thereof
AssigneesNew York University, PureTech Health LLC
InventorsShohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Claims17
A method for treating a galectin-9 expressing hematological malignancy in a human subject, comprising administering to the human subject an effective amount of a pharmaceutical composition comprising an antibody that binds human galectin-9, wherein the antibody comprises:
- (a) a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 361, a heavy chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 388, and a heavy chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 406 and
- (b) a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 328, a light chain complementary determining region 2 (CDR2) set forth as SEQ ID NO:
- 329, and a light chain complementary determining region 3 (CDR3) set forth as SEQ ID NO:
- 352.
Dependencies are inferred from the claim text.